These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 28359242)

  • 1. Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes.
    Ganguly BB
    Curr Cancer Drug Targets; 2017; 17(7):586-602. PubMed ID: 28359242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
    Stankov K; Stankov S; Katanic J
    Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents.
    Santini V; Melnick A; Maciejewski JP; Duprez E; Nervi C; Cocco L; Ford KG; Mufti G
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):231-45. PubMed ID: 23838480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
    Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
    Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
    Ball B; Zeidan A; Gore SD; Prebet T
    Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic changes in the myelodysplastic syndrome.
    Issa JP
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):317-30. PubMed ID: 20359628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpreting new molecular genetics in myelodysplastic syndromes.
    Abdel-Wahab O; Figueroa ME
    Hematology Am Soc Hematol Educ Program; 2012; 2012():56-64. PubMed ID: 23233561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.
    Khan H; Vale C; Bhagat T; Verma A
    Semin Hematol; 2013 Jan; 50(1):16-37. PubMed ID: 23507481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.
    Voso MT; Lo-Coco F; Fianchi L
    Curr Opin Oncol; 2015 Nov; 27(6):532-9. PubMed ID: 26352541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS
    J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
    Gore SD
    Leuk Res; 2009 Dec; 33 Suppl 2(Suppl 2):S2-6. PubMed ID: 20004793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
    Ishikawa T
    Int J Clin Oncol; 2014 Feb; 19(1):10-5. PubMed ID: 24357411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetics of myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Leukemia; 2014 Mar; 28(3):497-506. PubMed ID: 24247656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
    Xu F; Li X
    Expert Rev Hematol; 2012 Apr; 5(2):177-85. PubMed ID: 22475286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic aspects of MDS and its molecular targeted therapy.
    Yamazaki J; Issa JP
    Int J Hematol; 2013 Feb; 97(2):175-82. PubMed ID: 23054654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.